Objectives: The aim of this study was to investigate the effects of tibolone and conjugated equine estrogens (CEEs) plus medroxyprogesterone acetate (MPA) (CEE + MPA) on levels of serum C-reactive protein (CRP), an independent risk factor for cardiovascular disorders, in postmenopausal women.
Study Design: In this prospective randomized study, we randomly assigned 58 healthy postmenopausal women to CEE (0.625 mg/day) plus MPA (2.5 mg/day) (CEE + MPA) or tibolone (2.5 mg/day). The serum levels of CRP at 3 months after starting treatment were compared with baseline values for both therapies.
Results: After 3 months of treatment the median CRP levels increased by 29% in the CEE + MPA group and by 5% in the tibolone group. But, these changes did not have statistical significance (P=0.15, P=0.06, respectively).
Conclusions: Our findings show that neither tibolone nor CEE + MPA caused significant changes in serum CRP levels in postmenopausal women. The potential impact of hormone therapy on serum CRP levels should be investigated in ongoing clinical trials.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00404-005-0111-1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Calcium sources can increase mechanical properties of 3D printed bioactive hybrid bone scaffolds.
RSC Adv
November 2024
Department of Materials, Imperial College London London UK
Inorganic/organic hybrid biomaterials have been developed to obtain synergy of the inorganic and organic co-networks for implant and 3D printed scaffold applications, providing combinations of bioactivity, toughness and controlled biodegradation. SiO-CaO/PTHF/PCL-diCOOH sol-gel hybrids previously showed potential for osteogenesis due to the addition of calcium to the silicate network of the hybrid, using calcium methoxyethoxide (CME) as the calcium source. Here, we investigate other calcium sources to improve mechanical properties and printability of the hybrid inks.
View Article and Find Full Text PDFPurpose: Menopausal hormone therapy's influence on ovarian and endometrial cancers remains unsettled. Therefore, we assessed the long-term influence of conjugated equine estrogen (CEE) plus medroxyprogesterone acetate (MPA) and CEE-alone on ovarian and endometrial cancer incidence and mortality in the Women's Health Initiative randomized, placebo-controlled clinical trials.
Materials And Methods: Postmenopausal women, age 50-79 years, were entered on two randomized clinical trials evaluating different menopausal hormone therapy regimens.
JCO We report long-term colorectal cancer findings from the Women's Health Initiative trial where 16,608 postmenopausal women with a uterus were randomly assigned to daily conjugated equine estrogen (CEE) 0.625 mg, plus medroxyprogesterone acetate (MPA) 2.5 mg, or placebo.
View Article and Find Full Text PDFRelationship between menopausal hormone therapy and breast cancer: A nationwide population-based cohort study.
Int J Gynaecol Obstet
August 2024
Department of Obstetrics and Gynecology, Sanggye Paik Hospital, School of Medicine, Inje University, Seoul, Republic of Korea.
Objective: To explore the risk of breast cancer associated with menopausal hormone therapy (MHT), including the various progestogens used today.
Methods: The study included postmenopausal women over 40 years from the National Health Insurance Database in South Korea (2011-2014) who either used MHT for over 6 months (MHT group) or never used MHT (non-MHT group) and were matched 1:1 based on several variables using propensity score matching. Both groups were followed until 2020.
Menopausal hormone therapy increases the risk of gallstones: Health Insurance Database in South Korea (HISK)-based cohort study.
PLoS One
December 2023
Department of Internal Medicine, Sanggye Paik Hospital, School of Medicine, Inje University, Seoul, Republic of Korea.
Objective: To determine whether menopausal hormone therapy (MHT) increases the risk of gallstones and gallbladder cancer.
Design: A retrospective cohort study.
Patients Or Other Participants: Data from the Korea National Health Insurance Corporation was obtained between January 1, 2002, and December 31, 2019.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!